RT Journal Article SR Electronic T1 Network Assisted Analysis of De Novo Variants Using Protein-Protein Interaction Information Identified 46 Candidate Genes for Congenital Heart Disease JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.11.30.21267069 DO 10.1101/2021.11.30.21267069 A1 Xie, Yuhan A1 Jiang, Wei A1 Dong, Weilai A1 Li, Hongyu A1 Jin, Sheng Chih A1 Brueckner, Martina A1 Zhao, Hongyu YR 2021 UL http://medrxiv.org/content/early/2021/12/02/2021.11.30.21267069.abstract AB De novo variants (DNVs) with deleterious effects have proved informative in identifying risk genes for early-onset diseases such as congenital heart disease (CHD). A number of statistical methods have been proposed for family-based studies or case/control studies to identify risk genes by screening genes with more DNVs than expected by chance in Whole Exome Sequencing (WES) studies. However, the statistical power is still limited for cohorts with thousands of subjects. Under the hypothesis that connected genes in protein-protein interaction (PPI) networks are more likely to share similar disease association status, we develop a Markov Random Field model that can leverage information from publicly available PPI databases to increase power in identifying risk genes. We identified 46 candidate genes with at least 1 DNV in the CHD study cohort, including 18 known human CHD genes and 35 highly expressed genes in mouse developing heart. Our results may shed new insight on the shared protein functionality among risk genes for CHD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded in part by NIH grant R03HD100883-01A1 (Y.X. and H.Z.) and R01GM134005-01A1 (W.J., H.L., and H.Z.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This manuscript is a mainly methodology paper. The data used in this manuscript are all public available. The research has no procedure related to collecting human subject data.2,645 CHD data can be downloaded from the supplement of PMID28991257 (https://static-content.springer.com/esm/art%3A10.1038%2Fng.3970/MediaObjects/41588_2017_BFng3970_MOESM3_ESM.xlsx).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are available online at https://github.com/JustinaXie/NDATADNVde novo variantCHDcongenital heart diseaseWESWhole Exome SequencingPPIprotein-protein InteractionFDRfalse discovery rateMRFMarkov Random FieldGWASGenome-Wide Association Studies